Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: Cost-effectiveness evidence and NICE guidance

Rheumatology

Volumn 47, Issue 2, 2008, Pages 119-120

  Wailoo, Allan ^a   Bansback, Nick ^a,b   Chilcott, Jim ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ANKYLOSING SPONDYLITIS; BATH AS DISEASE ACTIVITY INDEX; BATH AS FUNCTIONAL INDEX; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG WITHDRAWAL; EDITORIAL; HUMAN; MATHEMATICAL MODEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CANADA; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; IMMUNOGLOBULIN G; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; STATE MEDICINE;

EID: 38649111982     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem294     Document Type: Editorial

References (11)

1. Ara R, Reynolds A, Conway P. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology 2007;46:1338-44.
2. Botteman MF, Hay JW, Luo MP, Gurry AS, Wong RL, van Hout BA. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology 2007;46:1320-28.
3. Kobelt G, Andlin-Sobocki P, Brophy S, Jönsonn L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost effectiveness of treatment with infliximab (Remicade). Rheumatology 2004;43:158-66.
4. Kobelt G, Sobocki P, Sieper J, Braun J. Comparison of the cost effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. Int J Technol Assess Health Care 2007;23:368-75.
5. McLeod C, Bagust A, Boland A et al. Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis: A systematic review & economic evaluation. Health Technol Assess 2007;11 http://guidance.nice.org.uk/page.aspx?o=394626, (8 August 2007, date last accessed).
6. Bansback N, Wailoo A. Comparisons of Submitted Models for the Appraisal of Etanercept, Adalimumab, and Infliximab for Ankylosing Spendylitis. Report by the Nice Decision Support Unit. 2007 Available at http://guidance.nice.org.uk/page.aspx?o=441923, (8 August 2007, date last accessed).
7. Wailoo A, Banaback N, Chilcott J. Ankylosing Spondylitis: A Comparison of Cost Effectiveness Models. Report by the Nice Decision Support Unit. 2007. Available at http://guidance.nice.org.uk/page.aspx?o=441926, (8 August 2007, date last accessed).
8. Jois RN, Gaffney K, Keat A. Anti-tumour necrosis factor therapy for ankylosing spondylitis-unresolved issues. Rheumatology 2007;46:899-901.
9. Drummond MF, Jefferson, TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Brit Med J 1996;313:275-83.
10. Weinstein MO, O'Brien B, Homberger J et al. Principles of good practice of decision analytic modeling in health care evaluation: Report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003;6:9-17.
11. Bansback N, Maetzel A, Drummond M et al. Consideratons and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis. J Rheumatol 2007;34:1178-83.